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Available online 8 June 2016Malignant struma ovarii (SO) is a rare tumor, and as a consequence, treatments and follow-up procedures are not
clearly established. Presented in this study are two cases of suspicious ovarian masses, resected and correspond-
ing tomalignant SO on histopathology. Similar to thyroid cancer, we proposed complementary radioiodine ther-
apy (131I) after total thyroidectomy (no malignancy was observed at this level in our two patients). Patients
underwent treatmentwith 3.7 GBq 131I followed by post-therapy whole-body scintigraphy, which can detect re-
sidual disease or occult metastases. Thyroid remnant ablation increases the sensitivity and speciﬁcity of follow-
up testing using serum thyroglobulin levels as a tumormarker. Our two patients remained disease-free for 3 and
5 years, respectively, after treatment.





Struma ovarii (SO) is a rare tumor deﬁned as a mature ovarian tera-
toma containing 50% or more thyroid tissue, and it accounts for approx-
imately 5% of all ovarian teratomas that are mostly benign. Malignant
transformation of SO is reported to occur in less than 5% of all cases,
and it is even less likely to lead to metastatic disease (5–6%) (Dardik
et al., 1999). Due to the rarity of this type of tumor, there has been a pau-
city of data in the literature pertaining to treatments and follow-up pro-
cedures for this tumor. After local resection of the ovarian tumor, no
consensus exists between surveillance alone and adjuvant treatment
(De Simone et al., 2003). Similar to thyroid cancers, we proposed thy-
roidectomy, required before radioactive iodine ablation (131I) and thy-
roxine suppressive therapy. We report two cases of malignant SO
treated in our institution: one patient with localized disease and the
other with lymph node and peritoneal extension.
2. Clinical cases
2.1. Case 1
A 49-year-old woman presented for evaluation of an asymptomatic
left ovarian mass, which was incidentally discovered during a routine
check of an intrauterine device (2012, October). Ultrasonography and
pelvic MRI exhibited an 8-cm-diameter left ovarian mass, mixeddicine, Oscar Lambret Center, 3
. This is an open access article undertumor with gadolinium enhancement of the posterior solid component
and low abundance intraperitoneal effusion. The appearance was con-
sistent with an ovarian mucinous adenocarcinoma.
The CA-125 levelwas elevated to 111U/ml (normal b 35),while CEA
and CA19-9 levels were normal. In December 2012, this patient
underwent laparoscopy with a total hysterectomy, bilateral salpingo-
oophorectomy with omentectomy, and pelvic-aortic lymphadenecto-
my. On pathological examination, the ovarian mass was a malignant
SO, consisting of follicular variants of papillary thyroid carcinoma
(7 × 5.5 × 3 cm) and no other histological features of malignancy. For
adjuvant therapy, it was proposed to treat this patient with procedures
similar to thyroid cancer, rather than other malignant ovarian cancers.
In February 2013, she underwent total thyroidectomy with the inten-
tion of administering 131I therapy as an adjuvant setting. On histological
examination, the thyroid consisted of normal tissue. Two months later,
the patient received a treatment dose of iodine 131 (3.7 GBq) after thy-
roxine withdrawal for four weeks. The thyroglobulin level was in-
creased to 19 ng/mL (TSH = 27 mIU/l), and serum thyroglobulin
antibodies were negative. Two days after treatment, the whole-body
131 I scintigraphy showed high uptake of cervical remnants (Fig. 1A
and B). The patient was maintained on thyroid hormone suppression
with thyroxine. Six months later, a diagnostic 131I scintigraphy
(185 MBq) was conducted after four weeks of thyroxine withdrawal,
which demonstrated complete remnant thyroid ablation (Fig. 1C and
D). Clinical examination, neck ultrasonography and thyroglobulin level
measurements were also negative (thyroglobulin b1 ng/ml, TSH =
43mIU/l), conﬁrming remission. Clinical and biological (TSH and thyro-
globulin) examination was planned every 6 months for two years and
annually thereafter. This patient has completed 3 years of follow-up
with no evidence of recurrence.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. A 49-year-old woman presented a left ovarian malignant struma ovarii resected followed two months later by a total thyroidectomy. (A and B) Whole-body scan (anterior and
posterior views) performed two days after 131I therapy (3.7 GBq) showed remnant thyroid tissue but no evidence of distant functioning metastasis. (C and D) Diagnostic whole body
scan (anterior and posterior views) of 131I (185 MBq) performed six months later, showing complete ablation of remnant tissues.
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A 67-year-old woman with a history of right nephrectomy for clear
cell carcinoma in 1986 presentedwith post menopausal bleeding in De-
cember 2010. Abdomino-pelvic ultrasonography showed uterine ﬁbro-
ma, a 4-cm left ovarian mass associated with a right retrocaval
adenopathy, without ascites. Pelvic MRI showed a left latero-uterine le-
sion (3.5 × 4 × 2.5 cm), hypo signal T1 and T2, without gadolinium en-
hancement. Appearancewas consistentwith a ﬁbroma or ﬁbrothecoma.
Further exploration by 18FDG PET showed a retrocaval lymph node and
left ovarianmass hypermetabolisms (Fig. 2). Bone scintigraphy and tho-
racic computed tomography were negative. Tumor markers were nor-
mal (CEA = 2.4 μg/l, CA125 = 28.2 U/ml, CA15–3 = 13 U/ml and
CA19-9 = 23 U/ml). In February 2011, she underwent a laparotomy
with total hysterectomy, bilateral salpingo-oophorectomy with
omentectomy, and paraaortic, retrocave and pelvic lymphadenectomy.
The left ovarian tumor measured 5.5 × 4 cm. Histological examination
showed malignant SO (papillary carcinoma type), associated with a
metastatic retrocaval lymph node (5× 2.5 × 4 cm) and omental nodules
(Fig. 3).
After the diagnosis of thyroid-type malignancy was established,
she had a total thyroidectomy (May 2011) with negative histology,
to optimize uptake of radioactive iodine 131 (3.7 GBq) six weeks
later. The 131 I post-therapeutic scintigraphy only showed thyroid
remnant uptake without abnormal abdominal uptake. The
stimulated serum thyroglobulin was lower than 1 ng/mL
(TSH N 100 mIU/ml).
Six months later, stimulated serum thyroglobulin, 18FDG PET, diag-
nostic 131I scintigraphy and neck ultrasonography were normal. The
subsequent follow-up consisted of a clinical examination and thyro-
globulin measurements performed every six months for two years and
annually thereafter. Pelvic MRIs performed 1 and 2 years after treat-
ment showed no evidence of recurrent disease. She remains free of dis-
ease 5 years later.3. Discussion
Most cases of malignant SO are incidentally discovered. The typical
presenting symptoms are pelvic pain, abnormal uterine bleeding and
abdominal or pelvic masses (De Simone et al., 2003; Yoo et al., 2008
Jun). It is rare for patients to present signs of hyperthyroidism (approx-
imately 7% of SO) (Matsuda et al., 2001 Sep).
DeSimone et al. (De Simone et al., 2003) reviewed approximately 24
cases of malignant SO: lesion sizes ranged from 5 to 20 cm, more com-
monly on the left side (63%), and most frequently with follicular vari-
ants of papillary thyroid carcinoma (54%) and papillary thyroid
carcinoma (21%). Our two clinical cases presented the same primary
characteristics.
CA125 is widely accepted as tumor marker of ovarian cancers and is
also elevated in other tumor lesions.Moreover, thismarker can increase
in non-malignant related gynecologic conditions (endometriosis, preg-
nancy) or as a secondary effect due to the presence of ascites (Leung &
Hammond, 1993; Jiang et al., 2010 Jul 29). In our two reported malig-
nant SO cases, the ﬁrst with ascites had increased CA125, while the sec-
ond patient (with peritoneal involvement but without ascites) had a
normal CA125 rate at diagnosis.
Because ovarian malignancies were suspected from the images, our
patients were ﬁrst treated with surgery, enabling histological diagnosis
and locoregional extent.
The cytological diagnostic criteria for papillary carcinoma are similar
to those described for the cervical thyroid gland, which include mitotic
activity, appearance of the cores (irregular, ground-glass) or vascular in-
vasion (Devaney et al., 1993 Oct). SOwithmetastasis is also classiﬁed as
a malignant disease.
Therapy for benign SO is surgical resection (Kunstmann & Fénichel,
2007 Jan). In malignant SO, surgery is also the ﬁrst phase of treatment.
A conservative surgery (unilateral salpingo-oophorectomy) may be ac-
ceptable in fertility-desiring patients if they have a localized tumor
(Salomon et al., 2003). A total hysterectomy with bilateral salpingo-
Fig. 2. 18FDG PET was performed in a 67-year-old woman with a left ovarian lesion and a history of right nephrectomy for clear cell carcinoma. (A) Coronal MIP image showed two
pathological 18FDG uptake (arrows). (B and C) Axial fused PET/CT images showed retrocaval lymph node (B) and left ovarian mass (C) hypermetabolisms. (D) Six months after
treatment, 18FDG PET coronal MIP image exhibited no pathological uptake.
58 A. Oudoux et al. / Gynecologic Oncology Reports 17 (2016) 56–59oophorectomy is a reasonable option in postmenopausal women or in
the case of extra ovarian extent (Makani et al., 2004 Sep). Currently,
no consensus exists on the postoperative treatment of patients with
malignant SO. It is commonlymanaged based on the treatments for thy-
roid carcinoma (De Simone et al., 2003; Willemse et al., 1987), taking
into account the stage and the aggressiveness of the disease.
Malignant SOmeasuring over 2 cm, disease outside the ovary, or ag-
gressive histological features should be treated by 131I ablation therapy.
Because normal thyroid concentrates 131I, total thyroidectomy is neces-
sary before radioiodine therapy (Luo et al., 2014 Nov). It generally con-
ﬁrms normal thyroid pathology and excludes a primary thyroid
carcinoma with subsequent metastasis to the ovary (10% of cases) or a
second thyroid cancer (Leong et al., 2013Dec). Similar to thyroid cancer,
the administration of 131I can treat residual ormetastatic disease and fa-
cilitates subsequent biological monitoring by serum thyroglobulin. In-
deed, monitoring serum thyroglobulin can be performed in malignant
SO in a manner analogous to patients with thyroid carcinoma. Thyro-
globulin is a protein precursor of thyroid hormones (T3 and T4), synthe-
sized and secreted by the thyroid follicular cells. Levels of thyroglobulinFig. 3. (A) Microscopic focus of papillary thyroid carcinoma in struma ovarii (×2are detectable in the serum and indicative of thyroid function. In thyroid
carcinoma, after thyroid suppression, thyroglobulin levels must be un-
detectable (b1 ng/ml). Increased thyroglobulin levels are indicative of
persistent or recurrent thyroid carcinoma (Rose et al., 1998). Post-ther-
apeutic 131I whole-body scintigraphy speciﬁes the extent of the disease.
For low-riskmalignant SO (thyroid carcinoma conﬁned to the ovarii,
measuring less than 2 cmwith noproblematic histological features), ad-
juvant therapy should be discussed. Suppressive thyroxine therapy is
then recommended, to reduce TSH secretion (serum TSH between 0.1
and 0.5 mIU/l). The disadvantage is that it is unlikely, due to the thyroid
still in place, that thyroglobulin becomes undetectable. Recurrence will
be suspected in cases with increasing thyroglobulin levels.
For monitoring after 131I therapy, we recommend:
- Six months after the end of treatment: clinical examination, serum
thyroglobulin measurements and diagnostic 131I scintigraphy (after
rhTSH stimulation or withdrawal).
- Every 6 months for 18 months and every year thereafter: the main-
stay follow-up of clinical examination and thyroglobulin00). (B) Omental nodule showing similar thyroid follicles (arrow) (×100).
59A. Oudoux et al. / Gynecologic Oncology Reports 17 (2016) 56–59measurements with TSH suppression (thyroglobulinmust be b1 ng/
ml). In the case of abnormal results, additional imagingmust be per-
formed (131I scintigraphy, 18FDG PET, ultrasonography, CT and/or
MRI). Pelvic locations can justify complementary imaging, adapted
to the initial stage of the disease. For our two clinical cases, pelvic
MRIswere performed1 and 2 years after therapy only for the patient
with the metastatic disease.
The prognosis of malignant SO is not well-characterized, given the
rarity of this disease. Localized forms have very good prognosis. Howev-
er, metastatic forms are also compatible with prolonged survival. In the
literature, recurrence occurs in approximately 15–35% of malignant SO
cases (De Simone et al., 2003; Makani et al., 2004 Sep). The average
time to recurrence is approximately 4–6 years, mostly in patients with-
out adjuvant therapy (De Simone et al., 2003; Jean et al., 2012 Apr). The
clinico-biological monitoring of SO (malignant and even benign) that
we recommend is for at least 20 years, cases of late recurrence having
been described (De Simone et al., 2003).
4. Conclusions
Malignant SO is a rare gynecologic tumor that is most often diag-
nosed by histological analysis after surgery for a suspicious ovarian
mass. After surgical resection of malignant SO, we suggest adjuvant
therapy with thyroidectomy followed by radioactive 131 I therapy and
suppressive thyroxine therapy. We recommend the same follow-up as
thyroid cancer associated with abdomino-pelvic evaluation. This moni-
toring should be extended for 20 years.
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